drugset / Trial / NCT06535308
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the BDNF/TRKβ and microglia-mediated IL-33/OPN signaling pathways; therefore, it is expected to be a promising new drug that can significantly improve symptoms associated with Alzheimer's disease, including memory loss.
Timeline
- Start
- 2024-10-22
- Primary completion
- 2026-04
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BnH-015B | Small molecule | 5 mg | Oral |
| Subject | BnH-015B | Small molecule | 10 mg | Oral |
| Subject | BnH-015B | Small molecule | 20 mg | Oral |
| Subject | BnH-015B | Small molecule | 40 mg | Oral |
| Subject | BnH-015B | Small molecule | 80 mg | Oral |
| Subject | BnH-015B | Small molecule | 160 mg | Oral |